JP2008505082A5 - - Google Patents

Download PDF

Info

Publication number
JP2008505082A5
JP2008505082A5 JP2007519321A JP2007519321A JP2008505082A5 JP 2008505082 A5 JP2008505082 A5 JP 2008505082A5 JP 2007519321 A JP2007519321 A JP 2007519321A JP 2007519321 A JP2007519321 A JP 2007519321A JP 2008505082 A5 JP2008505082 A5 JP 2008505082A5
Authority
JP
Japan
Prior art keywords
range
therapeutic agent
ratio
mitogen
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007519321A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505082A (ja
JP5122279B2 (ja
Filing date
Publication date
Priority claimed from US10/878,563 external-priority patent/US20050002899A1/en
Application filed filed Critical
Publication of JP2008505082A publication Critical patent/JP2008505082A/ja
Publication of JP2008505082A5 publication Critical patent/JP2008505082A5/ja
Application granted granted Critical
Publication of JP5122279B2 publication Critical patent/JP5122279B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007519321A 2004-06-29 2005-06-28 放射線を用いた治療及び／又は化学療法の前に癌を事前感作する方法、及び新規のサイトカイン混合物 Expired - Fee Related JP5122279B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/878,563 2004-06-29
US10/878,563 US20050002899A1 (en) 2003-07-03 2004-06-29 Method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture
PCT/US2005/022678 WO2006004633A2 (en) 2004-06-29 2005-06-28 A method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture

Publications (3)

Publication Number Publication Date
JP2008505082A JP2008505082A (ja) 2008-02-21
JP2008505082A5 true JP2008505082A5 (https=) 2008-08-21
JP5122279B2 JP5122279B2 (ja) 2013-01-16

Family

ID=35783284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007519321A Expired - Fee Related JP5122279B2 (ja) 2004-06-29 2005-06-28 放射線を用いた治療及び／又は化学療法の前に癌を事前感作する方法、及び新規のサイトカイン混合物

Country Status (8)

Country Link
US (1) US20050002899A1 (https=)
EP (1) EP1773368B1 (https=)
JP (1) JP5122279B2 (https=)
CN (1) CN101014354A (https=)
AU (1) AU2005260053A1 (https=)
CA (1) CA2571598A1 (https=)
ES (1) ES2581978T3 (https=)
WO (1) WO2006004633A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
CA2593648A1 (en) * 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
CN100344325C (zh) * 2005-10-17 2007-10-24 华南师范大学 一种治疗宫颈癌的药物及其制备方法与应用
US20080131396A1 (en) * 2006-12-04 2008-06-05 Cel-Sci Corp. Method for altering the CD4/CD8 ratio and the mononuclear cellular infiltrate into a tumor
CN102166347B (zh) * 2011-04-02 2013-12-11 广州市恺泰生物科技有限公司 一种白细胞介素-12的药物新用途
WO2025019822A1 (en) * 2023-07-19 2025-01-23 Istari Oncology, Inc. Methods of treatment with a chimeric poliovirus in patients with glioblastoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0789588B1 (en) * 1994-11-17 2005-01-19 University Of South Florida Method for making a medicament for treating secondary immunodeficiency
AU2002232560A1 (en) * 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
US20060257357A1 (en) * 2005-05-10 2006-11-16 Cel-Sci Corporation Method for modulating HLA class II tumor cell surface expression with a cytokine mixture

Similar Documents

Publication Publication Date Title
Aman et al. Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes
Yuzhalin et al. Interleukin-12: clinical usage and molecular markers of cancer susceptibility
Creagan et al. Phase II study of recombinant leukocyte A interferon (rIFN‐αA) in disseminated malignant melanoma
Lindemann et al. Biologic effects of recombinant human interleukin-3 in vivo.
JP2004533449A5 (https=)
Asadullah et al. Cytokines: interleukin and interferon therapy in dermatology
Weisbart et al. Physiology of granulocyte and macrophage colony-stimulating factors in host defense.
RU2008123556A (ru) Составы, имеющие цитокин модулирующие свойства
WO2005007086A3 (en) A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
Walsh et al. A trial of recombinant human interleukin‐1 in patients with severe refractory aplastic anaemia
JP2008505082A5 (https=)
Mackensen et al. Modulating activity of interferon-γ on endotoxin-induced cytokine production in cancer patients
Asadullah et al. Cytokine therapy in dermatology
Fibbe et al. The role of interleukin-1 in hematopoiesis
Cebon et al. The dissociation of GM‐CSF efficacy from toxicity according to route of administration: a pharmacodynamic study
Tritarelli et al. Adoptive immunotherapy with high-dose interleukin-2: kinetics of circulating progenitors correlate with interleukin-6, granulocyte colony-stimulating factor level
Staren et al. Overview of biological response modifiers
Tate et al. Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: clinical and laboratory effects
Cho et al. Psoriasiform eruption triggered by recombinant granulocyte-macrophage colony stimulating factor (rGM-CSF) and exacerbated by granulocyte colony stimulating factor (rG-CSF) in a patient with breast cancer
Feldmann et al. T cells and lymphokines
Shieh et al. Interleukin-1 modulation of cytokine receptors on human neutrophils: in vitro and in vivo studies
Adachi et al. Tumoricidal effect of human macrophage-colony-stimulating factor against human-ovarian-carcinoma-bearing athymic mice and its therapeutic effect when combined with cisplatin
Malkovska et al. Tumour immunotherapy
Ganser Clinical results with recombinant human interleukin-3
Bello-Fernandez et al. IL-4 acts as a homeostatic regulator of IL-2-induced TNF and IFN-gamma